Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon (NYSE: OGN) and Henlius announced the European Commission approval of POHERDY® (pertuzumab) on April 29, 2026, the first approved biosimilar to PERJETA in Europe for all reference-product indications.
POHERDY is indicated in combination with trastuzumab and chemotherapy for neoadjuvant, adjuvant, and metastatic HER2‑positive breast cancer. Organon holds exclusive global commercialization rights outside China under a 2022 license agreement with Henlius.
Sun Pharma (NYSE:—) to acquire Organon (NYSE:OGN) for US$14.00 per share in an all-cash deal valuing Organon at US$11.75 billion enterprise value. Transaction expected to close in early 2027, subject to regulatory approvals and Organon stockholder vote. Combined revenue projected at US$12.4 billion.
Organon reported 2025 revenue US$6.2B, Adjusted EBITDA US$1.9B, debt US$8.6B and cash US$574M. Sun Pharma expects Net Debt/EBITDA ~2.3x post-transaction.
Organon (NYSE: OGN) will release its first quarter 2026 financial results on May 7, 2026 and will host a webcast and conference call at 8:30 a.m. ET.
The company said it does not currently expect to record any milestone expense in Q1 2026, but results are preliminary and subject to closing procedures. The live webcast and a replay (available ~two hours after the call) can be accessed on the company website; dial-in details and Conference ID are provided for analysts and investors.
Organon (NYSE: OGN) announced VTAMA® (tapinarof) cream, 1% received a strong recommendation in the American Academy of Dermatology 2026 pediatric atopic dermatitis guidelines (published April 7, 2026).
The AAD named VTAMA the only steroid-free topical supported by high certainty of evidence indicated for children aged 2 years and older across all disease severities; approvals include FDA AD indication for ages 2+ (Dec 2024).
Organon (NYSE: OGN) reported pooled Phase 3 ADORING 1 and 2 results showing VTAMA cream 1% produced early, sustained improvements in atopic dermatitis down to age 2. Significant vIGA-AD, EASI75 and PP-NRS gains appeared by week 1 and increased through week 8 versus vehicle.
The analysis (N=813) showed EASI75 57.4% vs 22.1% at week 8 and 96.9% achieved some EASI improvement by week 8. Safety events ≥3% included folliculitis, headache, upper respiratory infection, and nasopharyngitis.
Organon (NYSE: OGN) presented a pooled Phase 3 sub-analysis from ADORING 1 and 2 showing VTAMA cream, 1% produced early and sustained improvements in patient‑reported sleep subdomains for pediatric atopic dermatitis patients down to age 2 and for affected family members through Week 8.
Key results: POEM sleep scores improved versus vehicle at Week 8: -1.9 vs -0.9 (age 2–6), -1.5 vs -1.0 (7–11), -1.2 vs -0.6 (12–17). DFI sleep subdomain also improved through Week 8. Reported common treatment‑emergent AEs (≥5%) included folliculitis, headache, and nasopharyngitis.
Organon (NYSE: OGN) entered an exclusive global license to MIUDELLA, Sebela's hormone-free copper IUD, with a $27.5 million closing payment, up to $505 million in sales-based milestones, and tiered double-digit royalties. The deal is subject to Hart-Scott-Rodino review and FDA approval of alternate supply-chain entities and other conditions.
MIUDELLA was FDA approved on February 24, 2025 for prevention of pregnancy up to three years, is not yet commercially available, and features a 3.7mm tapered inserter and a flexible frame.
Organon (NYSE: OGN) reported full year 2025 revenue of $6.2 billion (down 3% YoY) and diluted EPS of $0.72 (non-GAAP adj. EPS $3.66). Adjusted EBITDA was $1.91 billion with a 30.7% margin. Guidance for 2026 calls for ~$6.2B revenue and ~$1.9B Adjusted EBITDA, roughly in-line with 2025.
Q4 revenue fell 5% to $1.507B; Q4 net loss included a $301M goodwill impairment. The board declared a quarterly dividend of $0.02 payable March 12, 2026. Cash was $574M and debt $8.64B at year-end.
Organon (NYSE: OGN) will report fourth quarter and full year 2025 results on February 12, 2026 and host a webcast and conference call at 8:30 a.m. ET.
Organon said it does not currently expect to record any IPR&D or milestone expense in Q4 2025; results remain preliminary and are subject to quarter‑end closing procedures. A live webcast and a replay (available ~2 hours after the call) will be on the company investor website.
Organon (NYSE: OGN) announced on January 28, 2026 the closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
The release reiterates JADA's intended use for control and treatment of abnormal postpartum uterine bleeding and lists contraindications, warnings, and device-use instructions. For adverse events, call 844-JADAMOM.